[go: up one dir, main page]

NO994103D0 - Reverse hydroksamatderivater som metallproteaseinhibitorer - Google Patents

Reverse hydroksamatderivater som metallproteaseinhibitorer

Info

Publication number
NO994103D0
NO994103D0 NO994103A NO994103A NO994103D0 NO 994103 D0 NO994103 D0 NO 994103D0 NO 994103 A NO994103 A NO 994103A NO 994103 A NO994103 A NO 994103A NO 994103 D0 NO994103 D0 NO 994103D0
Authority
NO
Norway
Prior art keywords
protease inhibitors
metal protease
hydroxamate derivatives
reverse hydroxamate
reverse
Prior art date
Application number
NO994103A
Other languages
English (en)
Other versions
NO994103L (no
Inventor
Robert Carl Andrews
Dulce Garrido Bubacz
Joseph Howing Chan
Michael David Gaul
Darryl Lynn Mcdougal
David Lee Musso
Michael Howard Rabinowitz
Jennifer Badiang Stanford
Robert William Wiethe
Marc W Andersen
David John Cowan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO994103D0 publication Critical patent/NO994103D0/no
Publication of NO994103L publication Critical patent/NO994103L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Detergent Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO994103A 1997-02-26 1999-08-25 Reverse hydroksamatderivater som metallproteaseinhibitorer NO994103L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3911297P 1997-02-26 1997-02-26
PCT/EP1998/001015 WO1998038179A1 (en) 1997-02-26 1998-02-24 Reverse hydroxamate derivatives as metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
NO994103D0 true NO994103D0 (no) 1999-08-25
NO994103L NO994103L (no) 1999-10-25

Family

ID=21903750

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994103A NO994103L (no) 1997-02-26 1999-08-25 Reverse hydroksamatderivater som metallproteaseinhibitorer

Country Status (16)

Country Link
EP (1) EP1019386A1 (no)
JP (1) JP2001513767A (no)
KR (1) KR20000075681A (no)
AP (1) AP9901631A0 (no)
AR (1) AR013070A1 (no)
AU (1) AU6822398A (no)
BR (1) BR9807763A (no)
CA (1) CA2281664A1 (no)
HR (1) HRP980096A2 (no)
IS (1) IS5159A (no)
NO (1) NO994103L (no)
PE (1) PE59199A1 (no)
PL (1) PL335378A1 (no)
TR (1) TR199902063T2 (no)
WO (1) WO1998038179A1 (no)
ZA (1) ZA981532B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
CN1298299A (zh) 1998-02-07 2001-06-06 英国生物技术药物有限公司 抗菌剂
GB9818621D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therapeutic agents
EP1121118A4 (en) * 1998-08-26 2002-09-11 Glaxo Group Ltd FORMAMIDE-BASED THERAPEUTIC AGENTS
AU5688999A (en) * 1998-08-26 2000-03-21 Glaxo Group Limited Formamide compounds as therapeutic agents
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
GB9918869D0 (en) * 1999-08-10 1999-10-13 British Biotech Pharm Antibacterial agents
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2003066067A2 (en) 2002-02-04 2003-08-14 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
EP1622617A2 (en) * 2003-02-11 2006-02-08 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and tace-inhibitors
WO2007092899A2 (en) * 2006-02-09 2007-08-16 The Burnham Institute Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
DE602009000550D1 (de) 2008-03-25 2011-02-24 Affectis Pharmaceuticals Ag Neuartige P2X7R-Antagonisten und ihre Verwendung
KR20120006547A (ko) 2009-04-14 2012-01-18 어펙티스 파마슈티칼스 아게 신규한 p2x7r 길항제들 및 이들의 사용
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP2699242B1 (en) 2011-04-19 2017-11-01 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2013013179A1 (en) 2011-07-21 2013-01-24 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
DK0740652T3 (da) * 1994-01-20 1999-02-01 British Biotech Pharm Metalloproteinaseinhibitorer
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
ATE205184T1 (de) * 1995-11-23 2001-09-15 British Biotech Pharm Metalloproteinase inhibitoren

Also Published As

Publication number Publication date
PE59199A1 (es) 1999-06-24
CA2281664A1 (en) 1998-09-03
EP1019386A1 (en) 2000-07-19
WO1998038179A1 (en) 1998-09-03
AU6822398A (en) 1998-09-18
BR9807763A (pt) 2000-02-22
JP2001513767A (ja) 2001-09-04
HRP980096A2 (en) 1998-12-31
PL335378A1 (en) 2000-04-25
IS5159A (is) 1999-08-20
KR20000075681A (ko) 2000-12-26
AP9901631A0 (en) 1999-09-30
NO994103L (no) 1999-10-25
TR199902063T2 (xx) 1999-12-21
AR013070A1 (es) 2000-12-13
ZA981532B (en) 1999-08-24

Similar Documents

Publication Publication Date Title
NO994103D0 (no) Reverse hydroksamatderivater som metallproteaseinhibitorer
NO995433D0 (no) Protease-inhibitorer
NO20012980D0 (no) Proteaseinhibitorer
ATE259352T1 (de) Cysteine protease inhibitoren
EE200000385A (et) Sulfoonamiidi derivaadid kui aspartüülproteaasi inhibiitorid
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20002826L (no) Hydroksamsyrederivater som matriksmetallprotease (MMP) - inhibitorer
NO991922D0 (no) Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
NO992492D0 (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
NO975742D0 (no) Reversible cysteinproteasehemmere
NO990759D0 (no) Heterocykliske metallproteaseinhibitorer
NO992725L (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
ATE264339T1 (de) Serine protease inhibitoren
NO974403D0 (no) Reversible proteasehemmere
NO995435D0 (no) Protease-inhibitorer
NO20005196L (no) Substituerte pyrrolidinhydroksamat-metallproteaseinhibitorer
NO20004696L (no) Kinoloner som serinproteaseinhibitorer
ATE325091T1 (de) Aspartyl-protease inhibitoren
PT1047450E (pt) Combinacoes inibidor ace - inibidor mmp
NO995434D0 (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
NO20001924D0 (no) Isoquinoliner som urokinase-inhibitorer
NO20002938D0 (no) Fibrinolytisk inhibitor som forseglingsmateriale
DK0937036T3 (da) Substituerede 4-biphenyl-4-hydroxysmørsyrederivater som matrixmetalprotease-inhibitorer
NO20011654D0 (no) Benzamidderivater som trombininhibitorer